7:55AM BioSante reports 'positive' LibiGel safety data review for Phase III program (BPAX) 0.84 : Co announced that the independent Data Monitoring Committee has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. LibiGel (testosterone gel) is in development for the treatment of female sexual dysfunction, specifically, hypoactive sexual desire disorder in menopausal women.
News 
Market Data 
Discover 
